Progesterone cream versus oral progesterone: ask about endometrial protection

A progesterone cream should not be assumed to provide adequate endometrial protection simply because it is absorbed or seems to improve symptoms. For a person with a uterus using systemic estrogen, protection of the uterine lining requires evidence for the actual progestogen product, route, and regimen. Approved oral progesterone labeling and professional guidance do not make transdermal micronized-progesterone cream an interchangeable substitute.¹²

Define which job progesterone is meant to do

Ask the prescriber why the product is in the plan. Is the discussion about a symptom, a laboratory measurement, or opposition of estrogen’s effect on the endometrium? Those are different endpoints.

The PROMETRIUM oral-capsule label includes prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated-estrogen tablets.¹ That is a specific product-and-use statement, not a declaration that every preparation containing progesterone provides the same protection.

Write the intended job beside each prescribed hormone. A plan described only as “balancing estrogen and progesterone” can obscure which outcome is being monitored and which evidence supports it.

Absorption is a step, not the final outcome

A hormone reaching the bloodstream or changing a saliva measurement does not by itself demonstrate the intended effect in the uterine lining. The clinical question is whether the actual regimen adequately opposes estrogen at the relevant tissue.

British Menopause Society guidance says transdermal micronized progesterone has variable absorption and is unlikely to provide sufficient endometrial protection.² This is professional guidance from the United Kingdom, not an FDA approval document.

The distinction is also formulation-specific. A statement about micronized-progesterone cream should not be generalized to every hormone patch or every synthetic progestogen. Ask which molecule and delivery system the evidence actually studied.

What the original cream study contributes

In a small study of postmenopausal women receiving transdermal estrogen, investigators evaluated a particular sequential progesterone-cream regimen using endometrial samples and hormone measurements. The regimen did not produce the expected secretory endometrial change, and salivary progesterone values were too variable to guide that assessment reliably.³

That study does not determine an individual’s dose or prove that no progesterone crosses skin. Its value is narrower: absorption-related measurements and a protective tissue response cannot be treated as interchangeable evidence.

If a clinic cites a different cream study, ask whether it measured endometrial outcomes or only hormone levels, symptoms, or satisfaction. Also ask whether the studied preparation is the one being dispensed.

Separate three claims in the consultation

A blood or saliva target should not silently replace the endpoint in the third row. Ask the prescriber how the protection decision was made and what follow-up findings would change it.

This framework does not mean every person should switch to an oral product. Product contraindications, tolerability, the estrogen regimen, and individual history still require clinical assessment.

Establish whether the estrogen is systemic

The route’s name can be misleading. A vaginal product is not necessarily a low-exposure local preparation, and the need for a protection discussion depends on the actual treatment and patient context.

The local-versus-systemic vaginal-estrogen guide explains that distinction. Bring the exact estrogen product and instructions rather than relying on “a ring,” “a patch,” or “a cream.”

Also tell the clinician about prior hysterectomy or other relevant surgery. This article’s central question concerns uterine-lining protection; it should not be applied without establishing whether that tissue and clinical issue are present.

Read the finished-product status separately

“Bioidentical” does not identify the route’s evidence or the product’s approval. The approved-versus-compounded guide covers that regulatory distinction.

Ask for the exact dispensed preparation, pharmacy, instructions, and evidence supporting its assigned role. If a compounded cream is offered because another product is unsuitable, ask how the prescriber has addressed the protection question rather than assuming customization supplies missing evidence.

Do not stop, substitute, or change hormone treatment from this comparison. Bring an unclear regimen back to the prescriber for reconciliation.

Leave with the protective plan stated plainly

Ask: “Do I need endometrial protection with this estrogen regimen, which exact product provides it, and what evidence supports this route and schedule?”

The written answer should also explain whom to contact about bleeding changes or other concerns and when the regimen will be reviewed. A clear protection plan is a more useful outcome than a hormone-level target without a stated clinical purpose.